Singapore markets closed
  • Straits Times Index

    3,071.23
    +6.69 (+0.22%)
     
  • Nikkei

    30,500.05
    +176.71 (+0.58%)
     
  • Hang Seng

    24,920.76
    +252.91 (+1.03%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • BTC-USD

    47,923.34
    -714.00 (-1.47%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • FTSE Bursa Malaysia

    1,548.51
    -6.75 (-0.43%)
     
  • Jakarta Composite Index

    6,133.25
    +23.30 (+0.38%)
     
  • PSE Index

    6,912.85
    -55.58 (-0.80%)
     

Why Ocugen Stock Rose, Then Slipped Today

·1-min read
Why Ocugen Stock Rose, Then Slipped Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. Like many Ocugen bulls, LeBoyer is most excited about Covaxin. This is the coronavirus vaccine candidate currently being developed by Bharat Biotech, the American company's partner in India, in collaboration with the Indian Council of Medical Research-National Institute of Virology.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting